Valproic Acid Neuroprotection in the 6-OHDA Model of Parkinson's Disease Is Possibly Related to Its Anti-Inflammatory and HDAC Inhibitory Properties

Journal of Neurodegenerative Diseases
José Christian Machado XimenesGlauce Socorro de Barros Viana

Abstract

Parkinson's disease is a neurodegenerative disorder where the main hallmark is the dopaminergic neuronal loss. Besides motor symptoms, PD also causes cognitive decline. Although current therapies focus on the restoration of dopamine levels in the striatum, prevention or disease-modifying therapies are urgently needed. Valproic acid (VA) is a wide spectrum antiepileptic drug, exerting many biochemical and physiological effects. It has been shown to inhibit histone deacetylase which seems to be associated with the drug neuroprotective action. The objectives were to study the neuroprotective properties of VA in a model of Parkinson's disease, consisting in the unilateral striatal injection of the neurotoxin 6-OHDA. For that, male Wistar rats (250 g) were divided into the groups: sham-operated (SO), untreated 6-OHDA-lesioned, and 6-OHDA-lesioned treated with VA (25 or 50 mg/kg). Oral treatments started 24 h after the stereotaxic surgery and continued daily for 2 weeks, when the animals were subjected to behavioral evaluations (apomorphine-induced rotations and open-field tests). Then, they were sacrificed and had their mesencephalon, striatum, and hippocampus dissected for neurochemical (DA and DOPAC determinations), histological (...Continue Reading

References

Jan 1, 1988·Acta Neuropathologica·P L McGeerE G McGeer
Jan 1, 1997·Journal of Neural Transmission. Supplementum·Y GlinkaM B Youdim
May 17, 2000·Neurochemistry International·C U Johannessen
Dec 20, 2002·The Journal of Pharmacology and Experimental Therapeutics·Bin Liu, Jau-Shyong Hong
Oct 17, 2003·Current Drug Targets. Inflammation and Allergy·Christophe Wersinger, Anita Sidhu
Mar 26, 2005·FASEB Journal : Official Publication of the Federation of American Societies for Experimental Biology·Wei ZhangJing Zhang
Apr 19, 2005·Acta Psychiatrica Scandinavica. Supplementum·C L Bowden, V Singh
Jun 1, 2005·Behavioural Brain Research·Ruxandra IancuGesine Paul
Nov 30, 2005·Journal of Neurochemistry·Lyda M Rincón CastroLennard P Niles
Feb 8, 2006·Life Sciences·Benício N FreyFlávio Kapczinski
Feb 21, 2006·Lancet Neurology·K Ray ChaudhuriUNKNOWN National Institute for Clinical Excellence
Mar 28, 2006·Annals of Neurology·J William Langston
Jul 18, 2006·Pharmacology, Biochemistry, and Behavior·Lissiana Magna Vasconcelos AguiarGlauce Socorro B Viana
Sep 8, 2006·Movement Disorders : Official Journal of the Movement Disorder Society·Olivier RascolUNKNOWN 056 Study Group
Sep 16, 2006·Journal of Clinical Psychopharmacology·Gabriella GobbiNancy Leblanc
Mar 7, 2007·British Journal of Pharmacology·P S Whitton
May 31, 2008·Immunologic Research·Li Qian, Patrick M Flood
Apr 21, 2009·Lancet Neurology·K Ray Chaudhuri, Anthony H V Schapira
Sep 3, 2009·FASEB Journal : Official Publication of the Federation of American Societies for Experimental Biology·Na'ama A SheinEsther Shohami
Dec 8, 2009·Brazilian Journal of Medical and Biological Research = Revista Brasileira De Pesquisas Médicas E Biológicas·V RizelioA C Ferraz
Jan 7, 2011·Parkinson's Disease·J A PotashkinN K Runkle
Feb 12, 2011·The Korean Journal of Physiology & Pharmacology : Official Journal of the Korean Physiological Society and the Korean Society of Pharmacology·Yong Ri QianChoon Sang Bae
Feb 16, 2011·Movement Disorders : Official Journal of the Movement Disorder Society·Glenda M Halliday, Claire H Stevens
May 24, 2011·Computer Methods in Biomechanics and Biomedical Engineering·Laura M CunninghamDavid Craig
Jan 17, 2012·The International Journal of Neuropsychopharmacology·Lennard P NilesYi Pan
Apr 10, 2012·CNS & Neurological Disorders Drug Targets·Shams TabrezMohammad A Kamal
Jun 14, 2012·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Changgeng QianMaurizio Voi

❮ Previous
Next ❯

Citations

Feb 18, 2017·International Journal of Molecular Sciences·Zhengmao LiHongyu Zhang
Sep 2, 2017·Neurochemical Research·Francisco Arnaldo Viana LimaGlauce Socorro de Barros Viana
Mar 14, 2020·Environmental Toxicology·Shih-Wei HsuDa-Tian Bau
Aug 15, 2018·Neural Regeneration Research·Huan-Cheng WuOu-Mei Cheng
Jun 30, 2019·Integrative Biology : Quantitative Biosciences From Nano to Macro·Khaled YoussefPouya Rezai
Aug 3, 2021·Antimicrobial Agents and Chemotherapy·Marjan EnshaeiehMohammad Sayyah

❮ Previous
Next ❯

Software Mentioned

Image J

Related Concepts

Related Feeds

Basal Ganglia

Basal Ganglia are a group of subcortical nuclei in the brain associated with control of voluntary motor movements, procedural and habit learning, emotion, and cognition. Here is the latest research.

Amygdala and Midbrain Dopamine

The midbrain dopamine system is widely studied for its involvement in emotional and motivational behavior. Some of these neurons receive information from the amygdala and project throughout the cortex. When the circuit and transmission of dopamine is disrupted symptoms may present. Here is the latest research on the amygdala and midbrain dopamine.

Astrocytes

Astrocytes are glial cells that support the blood-brain barrier, facilitate neurotransmission, provide nutrients to neurons, and help repair damaged nervous tissues. Here is the latest research.

Astrocytes & Neurodegeneration

Astrocytes are important for the health and function of the central nervous system. When these cells stop functioning properly, either through gain of function or loss of homeostatic controls, neurodegenerative diseases can occur. Here is the latest research on astrocytes and neurodegeneration.

Astrocytes in Parkinson Disease

Parkinson's disease (PD) is a neurodegenerative disorder caused by the progressive loss of dopaminergic neurons. Some PD-genes may be associated with astrocyte dysfunction. Discover the latest research on astrocytes in Parkinson's disease here.